The International Space Station (ISS) National Laboratory has selected eight early-stage startups for the second cohort of its Orbital Edge Accelerator, twice the number of unnamed-program norms in early-stage space commercialization and a step up from the six companies the lab funded when it launched the program last year.

The more significant structural change is the program's split into two tracks. One track targets dual-use applications — technologies with both commercial and government or defense relevance. The other covers in-space manufacturing and space biology. The cohort's stated focus areas include semiconductors and biomanufacturing, according to the ISS National Lab's announcement.

For R&D managers, the two-track structure signals how the operator of the U.S. segment's national lab function is segmenting demand for orbital research. In-space manufacturing covers the production of materials whose properties benefit from microgravity — semiconductor-related work fits here, where crystal growth and defect behavior can differ from terrestrial processing. Space biology spans pharmaceutical and biomanufacturing research, an area where several companies have already run protein crystallization and tissue-engineering experiments on station.

The dual-use track is newer territory for an accelerator attached to a national laboratory. It reflects the broader alignment between civil space infrastructure and national-security technology priorities, and it positions the ISS National Lab to capture startups whose portfolios serve both markets. For startups, dual-use positioning can open non-dilutive government funding routes alongside venture capital.

The program's first year provides a limited but real baseline. Six startups received funding in the inaugural cohort. The expansion to eight companies across two tracks in year two represents roughly a 33% increase in cohort size, alongside a doubling of thematic focus areas. The lab has not disclosed per-company funding amounts for either cohort, so total program budget and the depth of each award remain open questions for anyone benchmarking this against terrestrial accelerators.

What the accelerator offers beyond capital matters for lab planning. Programs tied to the ISS National Lab typically provide access to the station's research environment, payload development support, and connections to implementation partners that handle flight hardware. For an early-stage company working on semiconductor processing or biomanufacturing, that access can substitute for capital that would otherwise go toward custom flight qualification.

The announcement names the focus areas but, as published, does not detail the individual companies, their technical milestones, or the funding terms. That limits what portfolio managers can assess today. Key questions worth tracking: which companies in the cohort have prior flight heritage, what measured results they must deliver to stay in the program, and how the dual-use track's selection criteria differ from the commercial track's.

The timing also carries weight. The ISS operates under a planned retirement horizon, with commercial successor platforms in development. An accelerator building an in-space manufacturing and biomanufacturing pipeline now is effectively seeding demand for whatever orbital infrastructure follows the station.

The ISS National Lab has committed to the eight startups for this cycle; whether the two-track format and the expanded cohort size hold for a third year will be the indicator to watch.